National Vision (EYE) Competitors $23.01 -0.16 (-0.69%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EYE vs. STVN, GKOS, NARI, IRTC, TMDX, BLCO, SLNO, INSP, PRCT, and NVSTShould you be buying National Vision stock or one of its competitors? The main competitors of National Vision include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry. National Vision vs. Its Competitors Stevanato Group Glaukos Inari Medical iRhythm Technologies TransMedics Group Bausch + Lomb Soleno Therapeutics Inspire Medical Systems PROCEPT BioRobotics Envista National Vision (NASDAQ:EYE) and Stevanato Group (NYSE:STVN) are both medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do analysts rate EYE or STVN? National Vision currently has a consensus target price of $18.67, suggesting a potential downside of 18.88%. Given National Vision's higher possible upside, equities research analysts clearly believe National Vision is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Vision 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is EYE or STVN more profitable? Stevanato Group has a net margin of 11.14% compared to National Vision's net margin of -1.40%. Stevanato Group's return on equity of 10.00% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets National Vision-1.40% 3.44% 1.40% Stevanato Group 11.14%10.00%6.03% Which has more risk & volatility, EYE or STVN? National Vision has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Does the media refer more to EYE or STVN? In the previous week, Stevanato Group had 3 more articles in the media than National Vision. MarketBeat recorded 8 mentions for Stevanato Group and 5 mentions for National Vision. National Vision's average media sentiment score of 1.08 beat Stevanato Group's score of 0.64 indicating that National Vision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Vision 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, EYE or STVN? Stevanato Group has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational Vision$1.82B1.00-$28.50M-$0.33-69.73Stevanato Group€1.19B6.21€127.45M€0.5148.06 SummaryStevanato Group beats National Vision on 10 of the 14 factors compared between the two stocks. Get National Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYE vs. The Competition Export to ExcelMetricNational VisionCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$1.83B$33.10B$16.04B$8.90BDividend YieldN/A2.83%3.18%4.13%P/E Ratio-69.7331.9219.4819.67Price / Sales1.001.8167.15110.29Price / Cash14.1615.9514.5827.49Price / Book2.228.686.145.42Net Income-$28.50M$1.19B$680.27M$248.34M7 Day Performance-0.35%0.45%0.02%0.81%1 Month Performance16.15%-0.16%-0.78%5.01%1 Year Performance81.61%32.45%5.58%18.10% National Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENational Vision2.5701 of 5 stars$23.01-0.7%$18.67-18.9%+75.8%$1.83B$1.82B-69.7313,411Positive NewsSTVNStevanato GroupN/A€23.62+1.4%N/A+33.6%€7.15B€1.19B46.315,521News CoveragePositive NewsAnalyst ForecastGap DownGKOSGlaukos4.4001 of 5 stars$96.80-3.3%$134.67+39.1%-12.6%$5.72B$383.48M-40.84780News CoverageNARIInari Medical0.4834 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.0358 of 5 stars$150.95+3.6%$138.60-8.2%+43.0%$4.65B$591.84M-48.072,000TMDXTransMedics Group1.5402 of 5 stars$127.53+3.2%$127.33-0.2%-11.0%$4.18B$441.54M93.77210Positive NewsBLCOBausch + Lomb3.3262 of 5 stars$12.01+2.3%$15.54+29.5%-10.3%$4.15B$4.79B24.4413,500SLNOSoleno Therapeutics4.6665 of 5 stars$81.42+1.8%$107.10+31.5%+105.3%$4.03BN/A-17.6230INSPInspire Medical Systems4.807 of 5 stars$129.88-0.8%$211.91+63.2%-3.4%$3.86B$802.80M59.851,246Positive NewsPRCTPROCEPT BioRobotics2.5162 of 5 stars$58.74-2.5%$90.00+53.2%-5.7%$3.33B$224.50M-34.55430NVSTEnvista3.4268 of 5 stars$18.90+0.1%$20.23+7.0%+17.7%$3.20B$2.51B-2.8912,300 Related Companies and Tools Related Companies STVN Alternatives GKOS Alternatives NARI Alternatives IRTC Alternatives TMDX Alternatives BLCO Alternatives SLNO Alternatives INSP Alternatives PRCT Alternatives NVST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYE) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding National Vision Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share National Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.